Silence Therapeutics (SLNCF)

[Wildbilly]

Silence Therapeutics plc Rating Reiterated by Canaccord Genuity (SLN)
Posted by Jim Brewer on Feb 27th, 2014 // No Comments

Silence Therapeutics plc (LON:SLN)‘s stock had its “buy” rating restated by stock analysts at Canaccord Genuity in a report issued on Thursday, Analyst Ratings News reports. They currently have a GBX 496 ($8.25) target price on the stock. Canaccord Genuity’s price objective would indicate a potential upside of 32.27% from the company’s current price.
Separately, analysts at N+1 Singer reiterated a “corporate” rating on shares of Silence Therapeutics plc in a research note on Thursday.

Silence Therapeutics plc (LON:SLN) opened at 375.00 on Thursday. Silence Therapeutics plc has a 52-week low of GBX 155.00 and a 52-week high of GBX 388.75. The stock’s 50-day moving average is GBX 315.6 and its 200-day moving average is GBX 256.6.
Silence Therapeutics plc (LON:SLN) is a biotechnology research and development company.